PHILADELPHIA--(BUSINESS WIRE)--Integral Molecular, Inc. has been selected to receive a five year, $9.1 million contract from the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health, to elucidate novel B cell epitopes on the surface of viral pathogens. Integral Molecular’s Shotgun Mutagenesis Mapping technology will be used to identify both linear and conformational epitopes on viral envelope proteins. By helping to define the full range of immunodominant structures on viral pathogens, Shotgun Mutagenesis will facilitate the design and development of improved vaccines against emerging infectious diseases. This is the second NIH award recently received by Integral Molecular for epitope mapping services.
